You are here: Industry Insights > EIB

News List

InvestEU: EIB Agrees to a €18 Million Loan to Estonian Biotech Icosagen for Innovative R&D Technologies and New cGMP Production Facility PharmaSources
February 09, 2023
The Estonian biopharmaceutical innovator Icosagen AS has reached a €18 million financing agreement with the EIB to further strengthen its drug discovery, development and production services.
EU to support novel antibiotics with €20 million funding europeanpharmaceuticalreview
April 15, 2021
BioVersys will receive €20 million in funding to support its development of new treatments for antimicrobial resistant infections.
BioVersys Gets EIB Funds to Address Antimicrobial Resistance contractpharma
April 15, 2021
The European Investment Bank (EIB) and BioVersys AG, a clinical-stage pharmaceutical company developing treatments for multidrug-resistant bacterial infections, signed a €20 million venture debt transaction.
EIB launches €50m Africa pharmaceutical manufacturing initiative pharmaceutical-business-review
December 23, 2020
The European Investment Bank launched the first ever scheme to strengthen local production of Active Pharmaceutical Ingredients in Africa and scale up drug manufacturing essential to improve public health.
EIB to support COVID-19 therapy with €24.5 million investment europeanpharmaceuticalreview
October 22, 2020
The European Investment Bank (EIB) will provide Immunic with up to €24.5 million to support the ongoing development of IMU-838, a potential COVID-19 therapy.
CureVac recieves €75 million loan for vaccine development and manufacturing expansion europeanpharmaceuticalreview
July 09, 2020
The European Investment Bank (EIB) will provide three €25 million instalments to support CureVac’s vaccine development and expansion to mRNA production facilities.
EIB Provides BioNTech with Debt Financing for COVID-19 Vaccine Development, Manufacturing americanpharmaceuticalreview
June 23, 2020
The European Investment Bank (EIB) and BioNTech SE concluded a €100 million debt financing agreement to support the development of BNT162, the company’s COVID-19 vaccine program.
BioNTech to receive up to €100m from EIB for vaccine development pharmaceutical-technology
June 15, 2020
German immunotherapy company BioNTech has signed a €100m debt financing agreement with the European Investment Bank (EIB) for the development of its Covid-19 vaccine candidate, BNT162.
European Investment Bank to provide BioNTech with up to €100 million in debt financing for COVID-19 vaccine development and manufacturing expresspharma
June 12, 2020
mRNA vaccines consist of genetic material, called messenger RNA, that provides instructions for a human cell to make a target protein, or immunogen, which activates the body’s immune response against the respective virus.
CEPI and European Investment Bank collaborate to Fund Vaccine Projects Europeanpharmaceuticalreview
May 07, 2020
The Coalition for Epidemic Preparedness Innovations (CEPI) and European Investment Bank (EIB) will work together to identify and fund vaccine projects for infectious diseases.

Previous page 1 2 Next page